1 March 2024

DILAPAN-S Achieves Recognition at SMFM 2024 Annual Pregnancy Meeting

At the SMFM 2024 Annual Pregnancy Meeting, DILAPAN-S distinguished itself with five abstracts selected for oral presentations or poster sessions, firmly establishing its role as a novel approach in labour induction. Among the diverse research presented, two studies stood out for their insights into the efficacy of DILAPAN-S compared to other methods of cervical ripening.

  1. The first, led by Antonio F. Saad et al., titled “Dilapan-S versus Standard Methods for Cervical Ripening in Term Pregnancies: An Individual Patient Data Meta-Analysis” (Am J Obstet Gynecol 2023;230:313 https://doi.org/10.1016/j.ajog.2023.11.603), concluded that „DILAPAN-S is at least non-inferior and marginally superior in reducing cesarean delivery rates when compared to other pre-induction cervical ripening agents. The study highlighted that parity plays a significant role in its efficacy, with multiparous women benefiting the most“.
  2. The second notable study, conducted by Rachel L. Wood et al., “Single-balloon catheter versus Dilapan-S placement for outpatient cervical ripening: A single-blind randomized controlled trial” (Am J Obstet Gynecol 2023;620 https://doi.org/10.1016/j.ajog.2023.11.1209), found that „Dilapan-S was non-inferior to cervical balloon catheter for outpatient cervical ripening based on change in Bishop score. Patients were significantly more satisfied with Dilapan-S and significantly less likely to experience cervical ripening failure or have unscheduled contact with the medical team compared to single balloon catheter”.

These findings underscore DILAPAN-S’s role as a preffered choice for healthcare professionals aiming to enhance patient satisfaction and outcomes in cervical ripening procedures.

For more information on the studies and their outcomes, visit the American Journal of Obstetrics & Gynecology website.

Any further information required?